Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Biochem Cell Biol ; 98: 54-64, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29510227

RESUMO

Cancerous cells show resistance to various forms of therapy, so applying up to the minute targeted therapy is crucial. For this purpose, long non-coding RNA PVT1 as shown by recent studies is an important oncogene that interacts with vital cellular signaling pathways and different proteins such as c-Myc, NOP2 and LATS2. Due to the enormous role of long non-coding RNAs in development of leukemias, we aimed to show the role of PVT1 knock-down on fate of different hematologic cell lines. owing to this matter, various experiments such as Real-time PCR, cell cycle analysis and apoptosis assay were performed. Meanwhile, proliferation rate by CFSE, protein expression of c-Myc and hTERT by western blot and flow cytometry analysis were investigated. Our results demonstrated that PVT1 knock-down results in c-Myc degradation, proliferation down-regulation, induction of apoptosis and G0/G1 arrest. Simultaneously, for the first time, we posited the relation between this oncogene with hTERT that reduced after PVT1 knock-down. Considering these results, long non-coding RNA PVT1 may be a potential option for targeted therapy in hematologic malignancies.


Assuntos
Biomarcadores Tumorais/genética , Neoplasias Hematológicas/genética , RNA Longo não Codificante/genética , Apoptose , Ciclo Celular , Proliferação de Células , Regulação Neoplásica da Expressão Gênica , Neoplasias Hematológicas/patologia , Neoplasias Hematológicas/terapia , Humanos , Terapia de Alvo Molecular , RNA Longo não Codificante/antagonistas & inibidores , RNA Interferente Pequeno/genética , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...